Insights

/

Clinical Insights

Drug Pipeline & Clinical Update - October 2026

Clinical Insights
November 6, 2026
Drug Pipeline & Clinical Update - October 2026
All set! Your report is ready.

Thanks for submitting the form. You can now download your report using the button below.

Download Report
Download Report

Transform health and pharmacy benefits

Talk to Our Team
Talk to Our Team
Listen on:

Listen on

Spotify

Listen on

Apple Podcast

Listen on

Amazon Music

Listen on

Audible

Listen on

iHeart Radio

Episode Guests
No items found.

Highlights

  • 2 key new drug approvals, including Hovilpri (pritelivir) oral tablet ‍
  • 6 notable expanded indications, including Ryzumvi® (phentolamine) – expanded to treat presbyopia in adults ‍
  • 1 Generic Launch: Adempas® (Riociguat) oral tablet  
  • Judi Rx's updated drug recall report: CLICK HERE to review.

Judi Health closely monitors the drug landscape to provide our clients with timely information on newly FDA approved medications and products in the pipeline. Please find the October 2026 Monthly Drug Update below:  

Key New Drug Approvals

Hovilpri (pritelivir) oral tablet

Approval Date: 10/09/2026

Indication: Treatment of mucocutaneous lesions caused by herpes simplex virus (HSV) infection that is refractory (with or without documented resistance) to treatment with acyclovir, valacyclovir, or famciclovir

Cost*: TBD

Key Consideration:

  • Recommended dose is 400 mg (4 tablets) on the day one, followed by 100 mg (1 tablet) once daily with or without food, until lesions have healed
  • Received priority review by the FDA

Press Release: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-treat-lesions-caused-herpes-simplex-virus  


‍

Hibsago (bepirovirsen) subcutaneous injection

Approval Date: 10/20/2026

Indication: Treatment of chronic HBV infection in adult patients without cirrhosis, in combination with nucleos(t)ide analog reverse transcriptase inhibitor (NrtI) therapy  

Cost*: TBD

Key Consideration:

  • Black box warning for hepatic flares and thrombocytopenia
  • Received priority review by the FDA

Press Release: https://us.gsk.com/en-us/media/press-releases/hibsago-bepirovirsen-approved-in-the-us-for-the-treatment-of-chronic-hepatitis-b-chb/  


‍

Notable Expanded Indications

  • Jaypirca® (pirtobrutinib) – expanded to treat adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) with no known 17p deletion  
  • Rhapsido® (remibrutinib) – expanded to treat symptomatic dermographism
  • Tukysa® (tucatinib) – expanded to treat adults with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting, in combination with trastuzumab and capecitabine
  • Velphoro® (sucroferric oxyhydroxide) – expanded to control serum phosphorus levels in patients 6 years of age and older with chronic kidney disease on dialysis
  • Ryzumvi® (phentolamine) – expanded to treat presbyopia in adults
  • Talzenna® (talazoparib) – expanded to treat metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer with HRR gene mutations, as detected by an FDA authorized test

‍

Generic Launches

  • Adempas® (Riociguat) oral tablet

‍

*Cost: actual patient out-of-pocket costs may be lower, as the list price does not reflect insurance coverage, co-pay support for eligible patients, or financial assistance from patient support

Download the Report
Download the Report
SHARE

Copied!

It's time to build your benefits, your way.

Get in touch to learn about our health benefit administration and transparent pharmacy benefit management solutions.

Talk to Our Experts
Talk to Our Experts